Credit Suisse Downgrades Esperion Therapeutics (ESPR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Esperion Therapeutics (ESPR) PT Lowered to $30 at Cowen
October 19, 2021 6:26 AM EDTCowen analyst Joseph Thome lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $30.00 (from $60.00) while maintaining an Outperform rating.
The analyst commented, "ESPR announced organizational changes to conserve cash in a challenging launch environment ahead of the Q1:23 CV Outcomes... More
Esperion Therapeutics (ESPR) PT Lowered to $22 at BTIG, Following Strategic Business Update
October 18, 2021 3:26 PM EDTBTIG analyst Thomas E. Shrader lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $22.00 (from $71.00) while maintaining a Buy rating.
... MoreEsperion Therapeutics (ESPR) PT Lowered to $27 at JMP Securities, Following Strategic Business Update
October 18, 2021 1:55 PM EDTJMP Securities analyst Jason N. Butler lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $27.00 (from $90.00) while maintaining a Market Outperform rating.
Analyst comments: "We have updated our model to reflect guidance, and are lowering our revenue projections and profit margins for... More
Esperion Therapeutics (ESPR) Announces Plan for Transformative Long-Term Growth, Updates Outlook
October 18, 2021 7:05 AM EDTEsperion (NASDAQ: ESPR) today announced its plan to align operational and expense structure to better enable future growth for its two first-in-class oral medicines, NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) and prioritize its investment in CLEAR Outcomes. The Company also issued updated expense guidance for fiscal year 2021 and fiscal year 2022 reflecting lower than previously estimated operating costs and pre-announced preliminary, unaudited U.S. net product revenue of $10.5 to $11.0 million for the quarter ended September 30, 2021.
In-person access to health care providers has been negatively impacted by the... More
4 Biotech Stocks Morgan Stanley Downgraded Today
October 14, 2021 6:59 AM EDTMorgan Stanley analyst Jeffrey Hung has reallocated ratings and adjusted price targets across the banks biotech research coverage.
The analyst downgraded shares of Neurocrine Biosciences (NASDAQ: NBIX) and Acadia Pharmaceutical (NASDAQ: ACAD) to Equal Weight from Overweight with price targets of $112.00 per share and $20.00 per share, respectively.
We continue to believe that negative news for dementia-related psychosis (DRP) are largely priced into ACAD shares and sentiment is overly cautious. In addition, we believe that the Street ascribes minimal value to pipeline programs. At current levels, we... More
Morgan Stanley Downgrades Esperion Therapeutics (ESPR) to Underweight
October 14, 2021 4:52 AM EDTMorgan Stanley analyst Jeffrey Hung downgraded Esperion Therapeutics (NASDAQ: ESPR) from Equalweight to Underweight with a price target of $11.00 (from $17.00).
For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.
Shares of Esperion Therapeutics closed at $10.40 yesterday.
... More